Colistin Versus Colistin Combined With Cefoperazone-sulbactam for Multiresistant Acinetobactor Baumannii Ventilator-associated Pneumonia Treatment

Colistin Versus Colistin Combined With Cefoperazone-sulbactam for Multiresistant Acinetobactor Baumannii Ventilator-associated Pneumonia Treatment

This study aims to evaluate clinical outcomes of colistin versus colistin in combination with cefoperazone-sulbactam for patients with MDR-AB VAP treatment.

MDR-AB (multidrug-resistant Acinetobacter baumannii) has been an increasingly common cause of ventilator-associated pneumonia (VAP) in intensive care unit (ICU). Colistin remains the last available antibiotic choice. Unfortunately, colistin monotherapy is often inadequate for microbiologic eradication and a risk factor of nephrotoxicity and for heteroresistance.

Inclusion Criteria:

• Patients with a diagnosis of VAP due to A. baumannii

Exclusion Criteria:

• patients who had polymicrobial VAP
• Patients with pre-existing severe renal failure and/or abnormal liver function tests
• Patients allergic to colistin or cefoperazone-sulbactam